Century Therapeutics Inc. set terms for its initial public offering on Monday, with plans to offer 10.6 million shares priced at $18 to $20 each. The company has applied to the list on Nasdaq, under the ticker symbol “IPSC.
JP Morgan, BofA Securities, SVB Leerink and Piper Sandler are underwriting the deal. Proceeds will be used to fund pre-clinical activity and research and development, as well as working capital and general corporate purposes. We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and haematological malignancies with significant unmet medical need.
The company is expanding its presence in uCity Square, opening 17,000 square feet of mixed office and laboratory space at 3624 Market Street, an additional 5,000 square feet of space at 3711 Market Street and has signed a lease for 25,000 square feet at 3535 Market Street within steps of the current headquarters at 3675 Market Street. Century has also committed to 33,000 square feet in the One uCity life sciences development currently under construction in the same burgeoning region of the city.